Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study

Diabetes

Volumn 52, Issue 3, 2003, Pages 812-817

  Spranger, Joachim ^a,b   Kroke, Anja ^b,c   Möhlig, Matthias ^a,b   Hoffmann, Kurt ^b   Bergmann, Manuela M ^b   Ristow, Michael ^a,b   Boeing, Heiner ^b   Pfeiffer, Andreas F H ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c RESEARCH INSTITUTE OF CHILD NUTRITION   (Germany)

Author keywords

CRP, C reactive protein; CV, coefficient of variation; ELISA, enzyme linked immunosorbent assay; EPIC, European Prospective Investigation into Cancer and Nutrition; IL, interleukin; LOQ, limit of quantification; OR, odds ratio

Indexed keywords

CYTOKINE; HEMOGLOBIN A1C; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING HABIT; SPORT;

ADULT; AGED; BLOOD GLUCOSE; BODY CONSTITUTION; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; EUROPE; EXERCISE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASMS; NUTRITION PHYSIOLOGY; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0345700727     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.3.812     Document Type: Article

References (25)

1. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345:790-797, 2001
2. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292, 1997
3. Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248, 1998
4. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353:1649-1652, 1999
5. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA: High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:455-461, 2002
6. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131-1137, 2002
7. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596-600, 2002
8. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384-2389, 2001
9. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
10. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H: Interferon beta 2/Bcell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 94:7251-7255, 1987
11. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454, 1999
12. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poll V: Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 180:1243-1250, 1994
13. Zheng H, Fletcher D, Kozak W, Jiang M, Hofmann KJ, Conn CA, Soszynski D, Grabiec C, Trumbauer ME, Shaw A, et al.: Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 3:9-19, 1995
14. Boeing H, Korfmann A, Bergmann MM: Recruitinent procedures of EPIC-Germany: European Investigation into Cancer and Nutrition. Ann Nutr Metab 43:205-215, 1999
15. Klipstein-Grobusch K, Georg T, Boeing H: Interviewer variability in anthropometric measurements and estimates of body composition. Int J Epidemiol 26:S174-S180, 1997
16. Kroke A, Bergmann MM, Lotze G, Jeckel A, Klipstein-Grobusch K, Boeing H: Measures of quality control in the German component of the EPIC study: European Prospective Investigation into Cancer and Nultrition. Ann Nutr Metab 43:216-224, 1999
17. Bergmann MM, Bussas U, Boeing H: Follow-up procedures in EPIC-Germany - data quality aspects: European Prospective Investigation Into Cancer and Nutrition. Ann Nutr Metab 43:225-234, 1999
18. Hallez S, Derouane A: Novelle methode de traitement de séries de données tronquées dans l'étude de la pollutions atmospherique. Sci Total Environ 22:115-123, 1982
19. Cornfield J: A method of estimating comparative rates from clinical data: applications to cancer of the lung, breast and cervix. J Natl Cancer Inst 11:1269-1275, 1951
20. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 285:2109-2113, 2001
21. Warram JH, Kopczynski J, Janka HU, Krolewski AS: Epidemiology of non-insulin-dependent diabetes mellitus and its macrovascular complications: a basis for the development of cost-effective programs. Endocrinol Metab Clin North Am 26:165-188, 1997
22. Harris MI, Flegai KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey 1988-1994. Diabetes Care 21:518-524, 1998
23. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108:437-446, 2001
24. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted dismption of Ikkbeta. Science 293:1673-1677, 2001
25. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321-1326, 2002